Document Detail

Influence of combined C-peptide and insulin administration on renal function and metabolic control in diabetes type 1.
MedLine Citation:
PMID:  8408474     Owner:  NLM     Status:  MEDLINE    
The possible influence of C-peptide on renal function and metabolic control in patients with type 1 diabetes was examined in a double blind, randomized study. Nine patients received insulin and equimolar amounts of biosynthetic human C-peptide for 1 month (group 1), and nine were given insulin only (group 2). C-Peptide levels in plasma ranged from 0.3-2.6 nmol/L in group 1 during the study, whereas group 2 had undetectable levels. The urinary excretion of albumin in group 1 was 21 +/- 6 micrograms/min before the study and decreased by 40% and 55% after 2 and 4 weeks, respectively (P < 0.05). No change was seen in group 2. The glomerular filtration rate fell by 6% after 2 and 4 weeks (P < 0.05) in group 1, whereas no change was observed in group 2. Fluorescein leakage across the blood-retinal barrier decreased by 30% in group 1 (P < 0.05) and was unaltered in group 2. Hemoglobin-A1c and fructosamine values decreased by 9-16% in group 1 (P < 0.05), but not in group 2. The findings suggest that administration of C-peptide plus insulin, compared to insulin alone, to type 1 diabetic patients may reduce glomerular permeability and improve metabolic control.
B L Johansson; A Kernell; S Sjöberg; J Wahren
Related Documents :
12098494 - Acupuncture increases cell proliferation and neuropeptide y expression in dentate gyrus...
23136004 - Analogs of bardoxolone methyl worsen diabetic nephropathy in rats with additional adver...
24529124 - Relationships among protein tyrosine phosphatase 1b, angiotensin ii, and insulin-mediat...
9493594 - Effect of antihypertensive treatment with doxazosin on insulin sensitivity and fibrinol...
23337144 - Management of hyperglycemia in diabetic patients with hematological malignancies during...
22959964 - Peripheral antinociceptive effect of anandamide and drugs that affect the endocannabino...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The Journal of clinical endocrinology and metabolism     Volume:  77     ISSN:  0021-972X     ISO Abbreviation:  J. Clin. Endocrinol. Metab.     Publication Date:  1993 Oct 
Date Detail:
Created Date:  1993-11-12     Completed Date:  1993-11-12     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0375362     Medline TA:  J Clin Endocrinol Metab     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  976-81     Citation Subset:  AIM; IM    
Department of Clinical Physiology, Karolinska Hospital, Stockholm, Sweden.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Blood Glucose / drug effects
Blood-Retinal Barrier / drug effects
C-Peptide / administration & dosage,  pharmacology,  therapeutic use*
Diabetes Mellitus, Type 1 / drug therapy*,  physiopathology
Double-Blind Method
Fluoresceins / pharmacokinetics
Glomerular Filtration Rate / drug effects
Glucagon / blood
Growth Hormone / blood
Hemoglobin A, Glycosylated / analysis
Hexosamines / blood
Insulin / administration & dosage,  pharmacology,  therapeutic use*
Insulin Infusion Systems
Kidney / drug effects*,  physiopathology
Norepinephrine / blood
Pilot Projects
Reg. No./Substance:
0/Blood Glucose; 0/C-Peptide; 0/Fluoresceins; 0/Hemoglobin A, Glycosylated; 0/Hexosamines; 11061-68-0/Insulin; 2321-07-5/Fluorescein; 4429-04-3/Fructosamine; 51-41-2/Norepinephrine; 9002-72-6/Growth Hormone; 9007-92-5/Glucagon

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Competitive polymerase chain reaction quantitation of c-erbA beta 1, c-erbA alpha 1, and c-erbA alph...
Next Document:  Thyroid hormone resistance syndrome: correlation of dominant negative activity and location of mutat...